-
2
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
IFNB Multiple Sclerosis Study Group
-
IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-61.
-
(1993)
Neurology
, vol.43
, pp. 655-661
-
-
-
3
-
-
0037442623
-
Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
-
Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ. 2003;326:388-92.
-
(2003)
BMJ
, vol.326
, pp. 388-392
-
-
Sudlow, C.L.1
Counsell, C.E.2
-
4
-
-
0033911466
-
Long-term treatment of multiple sclerosis with interferon-beta may be cost effective
-
Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics. 2000;18:45-53.
-
(2000)
Pharmacoeconomics
, vol.18
, pp. 45-53
-
-
Kendrick, M.1
Johnson, K.I.2
-
5
-
-
0034017018
-
Treatment of multiple sclerosis with interferon beta: An appraisal of cost-effectiveness and quality of life
-
Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-9.
-
(2000)
J Neurol Neurosurg Psychiatry
, vol.68
, pp. 144-149
-
-
Parkin, D.1
Jacoby, A.2
McNamee, P.3
-
6
-
-
0037426031
-
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
-
Chilcott, J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003;326:522-6.
-
(2003)
BMJ
, vol.326
, pp. 522-526
-
-
Chilcott, J.1
McCabe, C.2
Tappenden, P.3
-
7
-
-
33645968874
-
Multiple sclerosis - Beta interferon and glatiramer acetate (No. 32)
-
National Institute for Health and Clinical Excellence, London: NICE; Available online. URL: Accessed April 2006
-
National Institute for Health and Clinical Excellence, Multiple sclerosis - beta interferon and glatiramer acetate (No. 32). London: NICE; 2001. Available online. URL: http://www.nice.org.uk/ page.aspx?o=27588 Accessed April 2006.
-
(2001)
-
-
-
8
-
-
85049085863
-
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: Evaluating disease modifying treatments in multiple sclerosis
-
Miller DH. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:526.
-
(2003)
BMJ
, vol.326
, pp. 526
-
-
Miller, D.H.1
-
9
-
-
33645966399
-
Government to fund beta-interferon
-
News release issued by the Minister of Health, 26 December
-
Government to fund beta-interferon. News release issued by the Minister of Health, 26 December 1999.
-
(1999)
-
-
-
10
-
-
33645986352
-
MS patients welcome move to fund drugs
-
27 December
-
MS patients welcome move to fund drugs. New Zealand Herald, 27 December 1999.
-
(1999)
New Zealand Herald
-
-
-
11
-
-
33645973882
-
Pharmaceutical schedule
-
PHARMAC. Available online. URL: Accessed April
-
PHARMAC. Pharmaceutical schedule. Available online. URL: http://www.pharmac.govt.nz/pharmaceutical_schedule_update.asp Accessed April 2006.
-
(2006)
-
-
-
13
-
-
25844466246
-
-
Ministry for Disability Issues. Available online. URL: Accessed April 2006
-
Ministry for Disability Issues. NZ Disability Strategy; 2001. Available online. URL: http://www.odi.govt.nz/nzds/ about-the-strategy.html#objectives Accessed April 2006.
-
(2001)
NZ Disability Strategy
-
-
-
14
-
-
0036726904
-
Pharmacologic options for the management of multiple sclerosis symptoms
-
Schapiro RT. Pharmacologic options for the management of multiple sclerosis symptoms. Neurorehabilitation and Neural Repair. 2002;16:223-31.
-
(2002)
Neurorehabilitation and Neural Repair
, vol.16
, pp. 223-231
-
-
Schapiro, R.T.1
-
15
-
-
10344226168
-
A multimodal approach to managing the symptoms of multiple sclerosis
-
Crayton H,. Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63:S12-18.
-
(2004)
Neurology
, vol.63
-
-
Crayton, H.1
Heyman, R.A.2
Rossman, H.S.3
-
16
-
-
33645960317
-
Removal of expenditure cap for beta-interferon
-
[Letter from PHARMAC to MS Society of Auckland]; 7 March
-
Removal of expenditure cap for beta-interferon [Letter from PHARMAC to MS Society of Auckland]; 7 March 2002.
-
(2002)
-
-
|